Treatment of metastatic breast cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 5 SUPPL., 2014, Pages 759-761

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; DASATINIB; DOCETAXEL; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; PALBOCICLIB; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CIRCULATING TUMOR CELL; CONFERENCE PAPER; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; ANTAGONISTS AND INHIBITORS; BIOPSY; BREAST NEOPLASMS; DRUG RESISTANCE; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2;

EID: 84902489300     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0184     Document Type: Conference Paper

References (13)

1. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012;30:1919-1925.
2. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-444.
3. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-1670.
4. Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013;14:989-998.
5. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-529.
6. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer [abstract]. Presented at the 35th Annual San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, Texas. Abstract S1-6.
7. Paul D, Vukelja SJ, Holmes FA, et al. Letrozole plus dasatinib improves progression-free survival in hormone-receptor-positive, HER2-negative postmenopausal metastatic breast cancer patients receiving first-line aromatase inhibitor therapy [abstract]. Presented at the 36th San Antonio Breast Cancer Symposium; December 5-9, 2013; San Antonio, Texas. Abstract S3-07.
8. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-2724.
9. Smerage JB, Barlow WE, Hayes DF, et al. SWOG S0500: a randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment [abstract]. Presented at the 36th San Antonio Breast Cancer Symposium; December 5-9, 2013; San Antonio, Texas. Abstract S5-07.
10. Baselga J, Cortés J, Kim SB, et al CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
11. Wilks S, Puhalla S, O'Shaughnessy J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer [abstract]. Presented at the 36th San Antonio Breast Cancer Symposium; December 5-9, 2013; San Antonio, Texas. Abstract P4-12-12.
12. Verma S, Miles D, Gianni L, et al EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
13. Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol, in press.